LIPAC Oncology Names Daniel K. Spiegelman as Independent Board Advisor
MENLO PARK, Calif., May 13, 2021 /PRNewswire/ — LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Daniel K….
Comments Off on LIPAC Oncology Names Daniel K. Spiegelman as Independent Board Advisor